100 related articles for article (PubMed ID: 27407262)
1. Disease activity, quality of life and indirect costs of reduced productivity at work, generated by Polish patients with ankylosing spondylitis.
Kawalec P; Malinowski K
Reumatologia; 2015; 53(6):301-8. PubMed ID: 27407262
[TBL] [Abstract][Full Text] [Related]
2. Disease activity, quality of life and indirect costs of psoriatic arthritis in Poland.
Kawalec P; Malinowski KP; Pilc A
Rheumatol Int; 2016 Sep; 36(9):1223-30. PubMed ID: 27339273
[TBL] [Abstract][Full Text] [Related]
3. Disease activity, quality of life, and indirect costs of ulcerative colitis in Poland.
Kawalec P; Stawowczyk E; Mossakowska M; Pilc A
Prz Gastroenterol; 2017; 12(1):60-65. PubMed ID: 28337239
[TBL] [Abstract][Full Text] [Related]
4. Health-Related Quality of Life Impairment and Indirect Cost of Crohn's Disease: A Self-Report Study in Poland.
Holko P; Kawalec P; Mossakowska M; Pilc A
PLoS One; 2016; 11(12):e0168586. PubMed ID: 27992531
[TBL] [Abstract][Full Text] [Related]
5. Costs and work limitation of patients with ankylosing spondylitis in China.
Tu L; Rai JC; Cao S; Lin Z; Hu Z; Gu J
Clin Exp Rheumatol; 2014; 32(5):661-6. PubMed ID: 25234798
[TBL] [Abstract][Full Text] [Related]
6. Direct and indirect costs associated with ankylosing spondylitis and related disease activity scores in Turkey.
Akkoç N; Direskeneli H; Erdem H; Gül A; Kabasakal Y; Kiraz S; Balkan Tezer D; Hacıbedel B; Hamuryudan V
Rheumatol Int; 2015 Sep; 35(9):1473-8. PubMed ID: 25749712
[TBL] [Abstract][Full Text] [Related]
7. Relationship between physician-based assessment of disease activity, quality of life, and costs of ulcerative colitis in Poland.
Kawalec P; Stawowczyk E
Prz Gastroenterol; 2018; 13(1):61-68. PubMed ID: 29657613
[TBL] [Abstract][Full Text] [Related]
8. Costs and quality of life of patients with ankylosing spondylitis in Canada.
Kobelt G; Andlin-Sobocki P; Maksymowych WP
J Rheumatol; 2006 Feb; 33(2):289-95. PubMed ID: 16465660
[TBL] [Abstract][Full Text] [Related]
9. Work Productivity and Costs Related to Patients with Ankylosing Spondylitis, Rheumatoid Arthritis, and Psoriasis.
Kruntorádová K; Klimeš J; Šedová L; Štolfa J; Doležal T; Petříková A
Value Health Reg Issues; 2014 Sep; 4():100-106. PubMed ID: 29702796
[TBL] [Abstract][Full Text] [Related]
10. Understanding limitations in at-work productivity in patients with active ankylosing spondylitis: the role of work-related contextual factors.
Boonen A; Boone C; Albert A; Mielants H
J Rheumatol; 2015 Jan; 42(1):93-100. PubMed ID: 25362661
[TBL] [Abstract][Full Text] [Related]
11. The indirect costs of systemic autoimmune diseases, systemic lupus erythematosus, systemic sclerosis and sarcoidosis: a summary of 2012 real-life data from the Social Insurance Institution in Poland.
Kawalec PP; Malinowski KP
Expert Rev Pharmacoecon Outcomes Res; 2015; 15(4):667-73. PubMed ID: 26153642
[TBL] [Abstract][Full Text] [Related]
12. Costs of smoking-attributable productivity losses in Poland.
Lasocka J; Jakubczyk M; Siekmeier R
Adv Exp Med Biol; 2013; 755():179-87. PubMed ID: 22826065
[TBL] [Abstract][Full Text] [Related]
13. Cost of Illness, Quality of Life, and Work Outcomes in Active Ankylosing Spondylitis Patients Treated With Adalimumab in China.
Tu L; Xie Y; Liao Z; Jiang Y; Lv Q; Cao S; Wei Q; Gu J
Front Public Health; 2020; 8():602334. PubMed ID: 33330342
[No Abstract] [Full Text] [Related]
14. Healthcare costs and productivity losses directly attributable to ankylosing spondylitis.
Rafia R; Ara R; Packham J; Haywood KL; Healey E
Clin Exp Rheumatol; 2012; 30(2):246-53. PubMed ID: 22409861
[TBL] [Abstract][Full Text] [Related]
15. Impact of age, sex, physical function, health-related quality of life, and treatment with adalimumab on work status and work productivity of patients with ankylosing spondylitis.
Maksymowych WP; Gooch KL; Wong RL; Kupper H; van der Heijde D
J Rheumatol; 2010 Feb; 37(2):385-92. PubMed ID: 19955052
[TBL] [Abstract][Full Text] [Related]
16. Infliximab improves productivity and reduces workday loss in patients with ankylosing spondylitis: results from a randomized, placebo-controlled trial.
van der Heijde D; Han C; DeVlam K; Burmester G; van den Bosch F; Williamson P; Bala M; Han J; Braun J
Arthritis Rheum; 2006 Aug; 55(4):569-74. PubMed ID: 16874778
[TBL] [Abstract][Full Text] [Related]
17. Costs and quality of life of patients with ankylosing spondylitis in Hong Kong.
Zhu TY; Tam LS; Lee VW; Hwang WW; Li TK; Lee KK; Li EK
Rheumatology (Oxford); 2008 Sep; 47(9):1422-5. PubMed ID: 18635597
[TBL] [Abstract][Full Text] [Related]
18. The indirect costs of ankylosing spondylitis: a systematic review and meta-analysis.
Malinowski KP; Kawalec P
Expert Rev Pharmacoecon Outcomes Res; 2015 Apr; 15(2):285-300. PubMed ID: 25579502
[TBL] [Abstract][Full Text] [Related]
19. The unmet need for anti-tumour necrosis factor (anti-TNF) therapy in ankylosing spondylitis.
Barkham N; Kong KO; Tennant A; Fraser A; Hensor E; Keenan AM; Emery P
Rheumatology (Oxford); 2005 Oct; 44(10):1277-81. PubMed ID: 16105913
[TBL] [Abstract][Full Text] [Related]
20. Longitudinal Analyses of Presenteeism and Its Role as a Predictor of Sick Leave in Patients With Ankylosing Spondylitis.
Tran-Duy A; Nguyen TT; Thijs H; Baraliakos X; Heldmann F; Braun J; Boonen A
Arthritis Care Res (Hoboken); 2015 Nov; 67(11):1578-85. PubMed ID: 26216525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
